Reported Earnings • Aug 04
Second quarter 2026 earnings released: EPS: €1.66 (vs €1.57 in 2Q 2025) Second quarter 2026 results: EPS: €1.66 (up from €1.57 in 2Q 2025). Revenue: €159.4m (up 9.0% from 2Q 2025). Net income: €16.8m (up 6.0% from 2Q 2025). Profit margin: 11% (in line with 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €197, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 7x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 933% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €367 per share. Reported Earnings • May 05
First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025) First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Apr 29
Upcoming dividend of €2.10 per share Eligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%). Duyuru • Mar 25
AlzChem Group AG, Annual General Meeting, May 05, 2026 AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time. Buy Or Sell Opportunity • Mar 18
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Declared Dividend • Mar 02
Dividend increased to €2.10 Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%. Reported Earnings • Mar 02
Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024) Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Feb 28
AlzChem Group AG announces Annual dividend, payable on May 08, 2026 AlzChem Group AG announced Annual dividend of EUR 2.1000 per share payable on May 08, 2026, ex-date on May 06, 2026 and record date on May 07, 2026. New Risk • Dec 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to €157, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 911% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share. Buy Or Sell Opportunity • Nov 03
Now 22% undervalued The stock has been flat over the last 90 days, currently trading at €157. The fair value is estimated to be €200, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 17% per annum over the same time period. Reported Earnings • Nov 01
Third quarter 2025 earnings released: EPS: €1.61 (vs €1.22 in 3Q 2024) Third quarter 2025 results: EPS: €1.61 (up from €1.22 in 3Q 2024). Revenue: €141.1m (up 6.3% from 3Q 2024). Net income: €16.3m (up 32% from 3Q 2024). Profit margin: 12% (up from 9.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 114% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Sep 24
AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025 AlzChem Group AG announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 01
Second quarter 2025 earnings released: EPS: €1.57 (vs €1.41 in 2Q 2024) Second quarter 2025 results: EPS: €1.57 (up from €1.41 in 2Q 2024). Revenue: €147.9m (up 4.2% from 2Q 2024). Net income: €15.8m (up 10% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Buy Or Sell Opportunity • Jul 31
Now 33% overvalued after recent price rise Over the last 90 days, the stock has risen 20% to €151. The fair value is estimated to be €114, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €134, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 164% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €113 per share. Buy Or Sell Opportunity • Jun 26
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 41% to €137. The fair value is estimated to be €112, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Buy Or Sell Opportunity • Jun 05
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 51% to €134. The fair value is estimated to be €111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period. Duyuru • May 09
AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025 AlzChem Group AG announced that they will report first half, 2025 results on Jul 30, 2025 Valuation Update With 7 Day Price Move • May 07
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €125, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 9x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 541% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €113 per share. Duyuru • May 02
AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025 AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year. Reported Earnings • May 02
First quarter 2025 earnings released: EPS: €1.44 (vs €1.20 in 1Q 2024) First quarter 2025 results: EPS: €1.44 (up from €1.20 in 1Q 2024). Revenue: €149.9m (down 1.1% from 1Q 2024). Net income: €14.6m (up 20% from 1Q 2024). Profit margin: 9.7% (up from 8.0% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • May 02
Upcoming dividend of €1.80 per share Eligible shareholders must have bought the stock before 09 May 2025. Payment date: 13 May 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (4.6%). Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €103, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 428% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €197 per share. Duyuru • Mar 29
AlzChem Group AG, Annual General Meeting, May 08, 2025 AlzChem Group AG, Annual General Meeting, May 08, 2025, at 10:00 W. Europe Standard Time. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €88.46, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 343% over the past three years. New Risk • Mar 04
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change). Declared Dividend • Mar 03
Dividend increased to €1.80 Dividend of €1.80 is 50% higher than last year. Ex-date: 9th May 2025 Payment date: 13th May 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 02
Full year 2024 earnings released: EPS: €5.31 (vs €3.40 in FY 2023) Full year 2024 results: EPS: €5.31 (up from €3.40 in FY 2023). Revenue: €571.5m (up 4.7% from FY 2023). Net income: €54.1m (up 56% from FY 2023). Profit margin: 9.5% (up from 6.3% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jan 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Duyuru • Dec 06
Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025 AlzChem Group AG approved the appointment of Martina Spitzer as a new member of the Management Board for a term of three years from January 1, 2025 to December 31, 2027. In her new position as Chief Sales Officer (CSO), she will be responsible for the areas of Health & Nutrition (Creapure®), Fine Chemicals (Chemicals & Applications) and Sustainability (ESG). Ms. Spitzer’s appointment as CSO represents the next important step in the early succession planning for the Management Board. Ms. Spitzer is now already taking over two important business areas in sales, as Dr. Weichselbaumer will be in charge of the future project of setting up production in the USA. Ms. Spitzer has been with the Alzchem Group since 1999. In 2020, she was appointed Head of Alzchem’s entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she was instrumental in the introduction of the sustainability division, the optimization of central business processes and the implementation of forward-looking projects. Duyuru • Nov 27
AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025 AlzChem Group AG announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023) Third quarter 2024 results: EPS: €1.22 (up from €0.85 in 3Q 2023). Revenue: €132.7m (up 7.0% from 3Q 2023). Net income: €12.4m (up 44% from 3Q 2023). Profit margin: 9.3% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom. Duyuru • Nov 08
AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025 AlzChem Group AG announced that they will report fiscal year 2024 results on Feb 28, 2025 Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €51.80, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.39 per share. Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023) Second quarter 2024 results: EPS: €0.71 (up from €0.70 in 2Q 2023). Revenue: €139.9m (up 5.2% from 2Q 2023). Net income: €14.4m (up 100% from 2Q 2023). Profit margin: 10% (up from 5.4% in 2Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom. Duyuru • Aug 02
AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024 AlzChem Group AG announced that they will report Q3, 2024 results on Nov 07, 2024 Duyuru • May 09
AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024 AlzChem Group AG announced that they will report first half, 2024 results on Aug 01, 2024 Reported Earnings • May 01
First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023) First quarter 2024 results: EPS: €1.20 (up from €0.76 in 1Q 2023). Revenue: €153.6m (up 1.4% from 1Q 2023). Net income: €12.2m (up 59% from 1Q 2023). Profit margin: 7.9% (up from 5.1% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom. Declared Dividend • Mar 28
Dividend increased to €1.20 Dividend of €1.20 is 14% higher than last year. Ex-date: 8th May 2024 Payment date: 10th May 2024 Dividend yield will be 3.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 05
Full year 2023 earnings released: EPS: €3.40 (vs €2.97 in FY 2022) Full year 2023 results: EPS: €3.40 (up from €2.97 in FY 2022). Revenue: €554.5m (flat on FY 2022). Net income: €34.6m (up 15% from FY 2022). Profit margin: 6.2% (up from 5.5% in FY 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 30
AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024 AlzChem Group AG announced that they will report Q1, 2024 results on Apr 30, 2024 Duyuru • Oct 27
AlzChem Group AG to Report Fiscal Year 2023 Results on Mar 01, 2024 AlzChem Group AG announced that they will report fiscal year 2023 results on Mar 01, 2024 Duyuru • Sep 19
AlzChem Group AG to Report Q3, 2023 Results on Oct 26, 2023 AlzChem Group AG announced that they will report Q3, 2023 results on Oct 26, 2023 New Risk • Aug 05
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (44% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Aug 04
Second quarter 2023 earnings released: EPS: €0.71 (vs €0.95 in 2Q 2022) Second quarter 2023 results: EPS: €0.71 (down from €0.95 in 2Q 2022). Revenue: €128.5m (down 14% from 2Q 2022). Net income: €7.20m (down 25% from 2Q 2022). Profit margin: 5.6% (down from 6.5% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Duyuru • May 05
AlzChem Group AG to Report First Half, 2023 Results on Aug 03, 2023 AlzChem Group AG announced that they will report first half, 2023 results on Aug 03, 2023 Reported Earnings • May 05
First quarter 2023 earnings released: EPS: €0.76 (vs €0.76 in 1Q 2022) First quarter 2023 results: EPS: €0.76 (down from €0.76 in 1Q 2022). Revenue: €156.0m (up 19% from 1Q 2022). Net income: €7.67m (flat on 1Q 2022). Profit margin: 4.9% (down from 5.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: €2.96 (vs €2.72 in FY 2021) Full year 2022 results: EPS: €2.96 (up from €2.72 in FY 2021). Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Duyuru • Dec 09
AlzChem Group AG, Annual General Meeting, May 11, 2023 AlzChem Group AG, Annual General Meeting, May 11, 2023, at 10:00 Central European Standard Time. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: €0.59 (vs €0.46 in 3Q 2021) Third quarter 2022 results: EPS: €0.59 (up from €0.46 in 3Q 2021). Revenue: €145.1m (up 48% from 3Q 2021). Net income: €5.93m (up 27% from 3Q 2021). Profit margin: 4.1% (down from 4.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Duyuru • Oct 27
AlzChem Group AG to Report Fiscal Year 2022 Final Results on Feb 28, 2023 AlzChem Group AG announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Feb 28, 2023 Reported Earnings • May 12
First quarter 2022 earnings released: EPS: €0.76 (vs €0.78 in 1Q 2021) First quarter 2022 results: EPS: €0.76 (down from €0.78 in 1Q 2021). Revenue: €133.5m (up 23% from 1Q 2021). Net income: €7.70m (down 2.4% from 1Q 2021). Profit margin: 5.8% (down from 7.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11% compared to a 18% decline forecast for the industry in the United Kingdom. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS €0.46 (vs €0.37 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €98.1m (up 17% from 3Q 2020). Net income: €4.69m (up 25% from 3Q 2020). Profit margin: 4.8% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • May 07
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €108.3m (up 13% from 1Q 2020). Net income: €7.89m (up 80% from 1Q 2020). Profit margin: 7.3% (up from 4.6% in 1Q 2020). The increase in margin was driven by higher revenue. Upcoming Dividend • May 07
Upcoming dividend of €0.77 per share Eligible shareholders must have bought the stock before 13 May 2021. Payment date: 18 May 2021. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%). 
